Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Share-based Compensation (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Share-based Compensation for 11 consecutive years, with $4.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation changed N/A to $4.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.4 million, a N/A change, with the full-year FY2025 number at $13.3 million, up 183.13% from a year prior.
  • Share-based Compensation was $4.7 million for Q4 2025 at Crescent Biopharma, up from $405428.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $4.7 million in Q4 2025 to a low of -$2.6 million in Q4 2023.
  • A 5-year average of $1.0 million and a median of $963758.0 in 2022 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: tumbled 386.93% in 2023, then skyrocketed 40.7% in 2024.
  • Crescent Biopharma's Share-based Compensation stood at $1.3 million in 2021, then plummeted by 31.88% to $899201.0 in 2022, then crashed by 386.93% to -$2.6 million in 2023, then soared by 102.67% to $69000.0 in 2024, then skyrocketed by 6776.81% to $4.7 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Share-based Compensation are $4.7 million (Q4 2025), $405428.0 (Q1 2025), and $69000.0 (Q3 2024).